Ocugen is trading at MXN 16.96, down 10.74%, with no confirmed company-specific announcement explaining the October 12 decline.
- Provided market context shows no broad-market drop large enough to account for the move.
- Recent OCU410 Phase 2 ArMaDa coverage reported concern over stronger medium-dose efficacy than high-dose, despite positive overall findings; this does not confirm the current decline’s cause.
- Price context shows a sharp live decline after several reported closes at MXN 19.00; no current trading-volume information was available.